p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma

Histopathology

Volumn 68, Issue 4, 2016, Pages 615-618

  Beirne, James P ^a,b   Mcart, Darragh G ^a   James, Jacqueline A ^c   Salto Tellez, Manuel ^c   Maxwell, Perry ^c   Mccluggage, W Glenn ^a,b,d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E1; CYTOTOXIC AGENT; DIAMINOBENZIDINE; FORMALDEHYDE; HEMATOXYLIN; IMMUNOGLOBULIN; KI 67 ANTIGEN; PARAFFIN; PROTEIN P16; RETINOBLASTOMA BINDING PROTEIN 1; UNCLASSIFIED DRUG; RETINOBLASTOMA PROTEIN;

ANTIBODY COMBINING SITE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; COLLOID CARCINOMA; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; FEMALE; FEMALE GENITAL TRACT CANCER; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVARIAN TUBE HIGH GRADE SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STAINING; TREATMENT RESPONSE; CYSTADENOCARCINOMA; METABOLISM; OVARY TUMOR;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 84957938186     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12777     Document Type: Letter

References (4)

1. Milea A, George SHL, Matevski D et al. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod. Pathol. 2014; 27; 991-1001.
2. O'Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007; 50; 773-779.
3. Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int. J. Gynecol. Pathol. 2009; 28; 179-186.
4. Carser JE, Quinn JE, Michie CO et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol. Oncol. 2011; 123; 492-498.